How to buy Ocugen shares | $0.31

Ocugen, Inc is a biotechnology business with stocks listed in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$0.31 – a decrease of 9.36% over the previous week.

How to buy shares in Ocugen

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Ocugen. Find the share by name or ticker symbol: OCGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocugen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$0.31, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Ocugen, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Ocugen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Ocugen's share price?

Since the stock market crash in March caused by coronavirus, Ocugen's share price has had significant negative movement.

Its last market close was US$0.31, which is 40.04% down on its pre-crash value of US$0.517 and 19.23% up on the lowest point reached during the March crash when the shares fell as low as US$0.26.

If you had bought US$1,000 worth of Ocugen shares at the start of February 2020, those shares would have been worth US$553.46 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$596.15.

Ocugen share price

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

• Key figures

Information last updated 2020-09-20.

Latest market close	USD$0.31
52-week range	USD$0.15 - USD$3.25
50-day moving average	USD$0.4367
200-day moving average	USD$0.3433
Target price	USD$0.7
PE ratio	0.0515
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.8349

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ocugen, Inc by TradingView

Ocugen price performance over time

Historical closes compared with the last close of $0.31

1 week (2020-09-14)	-6.09%
1 month (2020-08-24)	-24.39%
3 months (2020-06-20)	N/A
6 months (2020-03-23)	7.71%

1 year (2019-09-20)	40.91%
2 years (2018-09-21)	-48.58%
3 years (2017-09-21)	-84.18%
5 years (2015-09-21)	-94.57%

Is Ocugen under- or over-valued?

Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ocugen's P/E ratio

Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ocugen financials

Revenue TTM	US$42,620
Gross profit TTM	US$0
Return on assets TTM	-60.93%
Return on equity TTM	-421.47%
Profit margin	0%
Book value	N/A
Market capitalisation	US$48.1 million

TTM: trailing 12 months

Shorting Ocugen shares

There are currently 325,123 Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 98.2% up from 164,051 last month.

There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.

Ocugen's "short interest ratio" (SIR)

Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 1.4 million). Ocugen's SIR currently stands at 0.23. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 230 shares are currently held short.

However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 40 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.

Find out more about how you can short Ocugen stock.

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 29 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen overview

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.

Frequently asked questions

• What percentage of Ocugen is owned by insiders or institutions?

  Currently 8.152% of Ocugen shares are held by insiders and 11.977% by institutions.

• When does the fiscal year end for Ocugen?

  Ocugen's fiscal year ends in December.

• Where is Ocugen based?

  Ocugen's address is: 5 Great Valley Parkway, Malvern, PA, United States, 19355

• What is Ocugen's CUSIP number?

  Ocugen's Committee on Uniform Securities Identification Procedures number is: 43358V109